Protagonist Therapeutics, Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Protagonist Therapeutics, Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($130.15M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $275.19M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($78.96M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($127.39M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | ($125.55M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($66.15M) | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | ($17.50M) | Mar 10, 2020 |
| FY2019 | Sep 30, 2019 | ($16.41M) | Mar 10, 2020 |
| FY2019 | Jun 30, 2019 | ($29.17M) | Mar 10, 2020 |
| FY2019 | Mar 31, 2019 | ($14.10M) | Mar 10, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($158.13M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $252.84M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($93.65M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($131.37M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | ($125.85M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($64.52M) | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | ($17.30M) | Mar 10, 2020 |
| FY2019 | Sep 30, 2019 | ($17.17M) | Mar 10, 2020 |
| FY2019 | Jun 30, 2019 | ($31.41M) | Mar 10, 2020 |
| FY2019 | Mar 31, 2019 | ($14.65M) | Mar 10, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $159.29M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $138.13M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $120.16M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $126.22M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $126.01M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $74.51M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $65.00M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $59.50M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $46.18M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $25.71M | Mar 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.67M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $184.15M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($70.24M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($108.14M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | ($107.87M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($72.48M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | ($41.53M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($49.95M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $3.87M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | ($29.97M) | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.59M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.36M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $609.0K | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $795.0K | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $1.10M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $471.0K | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $967.0K | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $486.0K | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $666.0K | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $347.0K | Mar 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $668.19M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $744.73M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $357.95M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $247.93M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $347.70M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $324.47M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $154.92M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $139.47M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $163.73M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $93.99M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.48M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $69.43M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $21.27M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $32.32M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $47.67M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $44.86M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $74.95M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $26.96M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $43.10M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $6.44M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $614.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $675.30M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $336.68M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $215.61M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $300.02M | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $279.61M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $79.96M | Mar 15, 2023 |
| FY2021 | Dec 31, 2018 | $112.52M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $120.63M | Mar 10, 2021 |
| FY2019 | Dec 31, 2016 | $87.56M | Mar 10, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($470.67M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($340.52M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($615.71M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($536.76M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($409.36M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($283.81M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($217.66M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($140.47M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($101.55M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($64.59M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.39M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $97.25M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $186.73M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $125.74M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $123.67M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $117.36M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $33.01M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $82.23M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $106.03M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $21.08M | Mar 12, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $9.79M | Mar 10, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 62.58M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 61.04M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 57.71M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 49.34M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 47.84M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 43.75M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 27.22M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 23.19M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 21.09M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 16.72M | Mar 7, 2018 |